The GNPTG Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population in which the GNPTG gene has been disrupted to generate a loss-of-function model. Provided as a polyclonal pool, this heterogeneous population enables robust study of the gamma subunit of GlcNAc-1-phosphotransferase in human lung carcinoma-derived epithelial cells.
The A-549 cell line is an adherent epithelial cell line derived from human lung adenocarcinoma. It is a widely used model in cancer biology due to its robust growth, stable karyotype, and relevance to lung cancer pathology. This host background is particularly suitable for investigating lysosomal function, autophagy, and secretory pathways within the context of lung carcinoma.
GNPTG encodes the gamma subunit of GlcNAc-1-phosphotransferase, which partners with the alpha and beta subunits (GNPTAB) to form the active enzyme complex responsible for adding mannose-6-phosphate (M6P) tags to lysosomal hydrolases. These tags are essential for M6PR-mediated sorting to lysosomes. Disruption of GNPTG impairs complex activity, leading to hypophosphorylation and missorting of hydrolases such as cathepsin D and beta-glucuronidase, causing their hypersecretion. Transcription of GNPTG is regulated by the mTORC1-TFEB/MITF/TFE3 axis, linking lysosomal biogenesis to nutrient status.
In A-549 cells, GNPTG knockout results in profound lysosomal enzyme missorting and secretion, recapitulating features of mucolipidosis III gamma. This deficiency compromises lysosomal degradative capacity, affecting autophagy and cellular homeostasis. Since lysosomal function influences cancer cell metabolism, drug resistance, and immune evasion, this model provides a valuable platform to study lysosomal dysfunction in lung adenocarcinoma. The polyclonal population reduces clonal artifacts and better reflects genetic heterogeneity.
The GNPTG Knockout A-549 Polyclonal Cells are suitable for a range of applications, including western blotting of secreted lysosomal enzymes, immunofluorescence to assess enzyme localization, activity assays in conditioned media, co-immunoprecipitation of the GNPTAB complex, and transcriptomic profiling via RNA-seq. Key research areas include lysosomal enzyme trafficking, mucolipidosis III gamma pathology, drug screening for lysosomal storage disorders, and lysosomal biogenesis studies. For more information, please contact Ascent Research.
